Inventiva SA logo

Inventiva SANASDAQ: IVA

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

France

IPO:

10 July 2020

Next earnings report:

26 March 2025

Last dividends:

N/A

Next dividends:

N/A
$149.23 M
-74%vs. 3y high
49%vs. sector
-vs. 3y high
-vs. sector
-131%vs. 3y high
8%vs. sector
-vs. 3y high
-vs. sector

Price

after hours | Wed, 20 Nov 2024 23:48:12 GMT
$2.85+$0.11(+4.01%)

Dividend

No data over the past 3 years
$1.34 M$1.34 M
No data over the past 3 years

Analysts recommendations

Institutional Ownership

IVA Latest News

Inventiva will present data from the final analysis of the Phase 2 study evaluating the combination of lanifibranor with empagliflozin in patients with MASH and T2D at the AASLD The Liver Meeting® late-breaker session
globenewswire.com15 November 2024 Sentiment: POSITIVE

Daix (France), Long Island City (New York, United States), November 15, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), also known as non-alcoholic steatohepatitis (“NASH”), and other diseases with significant unmet medical needs, today announced the presentation of the final analysis of LEGEND, Phase 2 proof-of-concept clinical trial, evaluating lanifibranor in combination with empagliflozin in patients with MASH and Type 2 Diabetes (T2D). The data will be presented Monday November 18, 2024, as a late breaker poster at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting®, taking place in San Diego California.

Inventiva announces a late breaker abstract from LEGEND, Phase 2 trial, evaluating lanifibranor in combination with empagliflozin in MASH at the AASLD The Liver Meeting® 2024
globenewswire.com21 October 2024 Sentiment: POSITIVE

Daix (France), Long Island City (New York, United States), October 21, 2024 - Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with metabolic dysfunction-associated steatohepatitis (“MASH”), also known as non-alcoholic steatohepatitis (“NASH”), today announced that the results of the Phase 2, LEGEND, evaluating lanifibranor in combination with empagliflozin in patients with MASH and Type-2-Diabetes (“T2D”) has been accepted as late breaker by the scientific committee of the upcoming 75th Annual American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2024 being held November 15 to 19, 2024 in San Diego, California.

Inventiva announces the availability of a prospectus in connection with its financing through the issuance of ordinary shares and pre-funded warrants
globenewswire.com14 October 2024 Sentiment: POSITIVE

Daix (France), Long Island City (New York, United States), October 14, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”) and other diseases with significant unmet medical needs, today announces that the Autorité des marchés financiers (the “AMF”) has approved a prospectus under no. 24-432, on October 14, 2024, in connection with its financing through the issuance of ordinary shares and pre-funded share warrants

Inventiva announces Filing of 2024 Half-Year Report – Conditions for Accessing or Consulting the Report
globenewswire.com14 October 2024 Sentiment: POSITIVE

Daix (France), Long Island City (New York, United States), October 14, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), also known as non-alcoholic steatohepatitis (“NASH”), and other diseases with significant unmet medical needs, today announced the filing, for the six-month period ended June 30, 2024 of its Half-Year Report (the “2024 Half-Year Report”) with the French financial markets authority, “Autorité des Marchés Financiers” (“AMF”).

Inventiva announces financing of up to €348 million to advance the NATiV3 Phase 3 MASH study
globenewswire.com14 October 2024 Sentiment: POSITIVE

Daix (France), Long Island City (New York, United States), October 14, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”) and other diseases with significant unmet medical needs, today announced financing of immediately €94.1 million and up to €348 million (the “Transaction”), subject to satisfaction of specified conditions, to fund the completion of the Phase 3 NATiV3 MASH trial and preparation for the potential filing for marketing approval and commercialization of lanifibranor.

Inventiva (IVA) Loses -17.66% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
zacks.com01 October 2024 Sentiment: POSITIVE

Inventiva (IVA) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Inventiva provides a corporate update and reports its unaudited 2024 first-half financial results
globenewswire.com25 September 2024 Sentiment: POSITIVE

Daix (France), Long Island City (New York, United States), September 25, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), also known as non-alcoholic steatohepatitis (“NASH”), and other diseases with significant unmet medical needs, today provided a corporate and a financial update for the six months ended June 30, 2024.

Half-Year Review of Inventiva's Liquidity Contract with Kepler Cheuvreux
globenewswire.com19 July 2024 Sentiment: POSITIVE

Daix (France), Long Island City (New York, United States), July 19, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with metabolic dysfunction-associated steatohepatitis (“MASH”), also known as non-alcoholic steatohepatitis (“NASH”), and other diseases with significant unmet medical needs, today announced the half-year report of its liquidity contract with Kepler Cheuvreux.

Inventiva announces a €20.1 million issuance of royalty certificates
globenewswire.com18 July 2024 Sentiment: POSITIVE

Daix (France), Long Island City (New York, United States), July 18, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with metabolic dysfunction-associated steatohepatitis (“MASH”), also known as non-alcoholic steatohepatitis (“NASH”), and other diseases with significant unmet medical needs, today announced the issuance of royalty certificates (the “Royalty Certificates”) subscribed by Samsara BioCapital, BVF Partners, NEA, Sofinnova, and Yiheng, for an amount of approximately €20.1 million  (the “Transaction”).

Inventiva provides an update on its NATiV3 clinical program evaluating lanifibranor in patients with MASH/NASH and its financial position
globenewswire.com05 July 2024 Sentiment: POSITIVE

Daix (France), Long Island City (New York, United States), July 5, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with metabolic dysfunction-associated steatohepatitis (“MASH”), also known as non-alcoholic steatohepatitis (“NASH”), and other diseases with significant unmet medical needs, today provided an update on its clinical program evaluating lanifibranor for the treatment of MASH/NASH and its financial position.

What type of business is Inventiva SA?

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company was founded in 2011 and is headquartered in Daix, France.

What sector is Inventiva SA in?

Inventiva SA is in the Healthcare sector

What industry is Inventiva SA in?

Inventiva SA is in the Biotechnology industry

What country is Inventiva SA from?

Inventiva SA is headquartered in France

When did Inventiva SA go public?

Inventiva SA initial public offering (IPO) was on 10 July 2020

What is Inventiva SA website?

https://www.inventivapharma.com

Is Inventiva SA in the S&P 500?

No, Inventiva SA is not included in the S&P 500 index

Is Inventiva SA in the NASDAQ 100?

No, Inventiva SA is not included in the NASDAQ 100 index

Is Inventiva SA in the Dow Jones?

No, Inventiva SA is not included in the Dow Jones index

When was Inventiva SA the previous earnings report?

No data

When does Inventiva SA earnings report?

The next expected earnings date for Inventiva SA is 26 March 2025